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Table 2. SNP genotype frequency distribution and association with stroke. 
Results were adjusted for significant covariates. Odds Ratio (OR) >1 indicates 
increased probability of having a stroke for the carriers of the minor allele.  
Variants in the inflammatory IL6 and MPO 
genes modulate stroke susceptibility through 
main effects and gene-gene interactions  
Table 1. Demographic and clinical characteristics of stroke patients.  
*Mann-Whitney test or χ2 test.  SD – standard deviation, yrs – years.  
Table 3. Gene X Gene interaction models obtained using the multifactor-
dimensionality reduction (MDR) method in stroke susceptibility;  
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Age, mean±SD (yrs) 62.9±6.8 52.2±9.1 <10
-4
Gender (male),  n/N (%) 247/530 (46.6) 428/672 (63.7) <10
-4
Stroke Type, n/N (%)
Ischemic stroke – 551/672 (82.0) – 
Hemorrhagic stroke – 111/672 (16.5) – 
Unknow type of stroke – 10/672 (1.5) – 
Stroke Risk Factors, n/N (%)
Hypertension (>85-140 mmHg) 193/513 (37.6) 369/601 (61.4) <10
-4
Diabetes 59/501 (11.8) 102/628 (16.2) 0.033
Hypercholesterolemia (cholesterol >200 mg/dL) 328/520 (63.1) 385/623 (61.8) 0.657
Smoking status 147/512 (28.7) 308/660 (46.7) <10
-4
Drinking status 218/505 (43.2) 388/662 (58.6) <10
-4
Characteristic P
*Patients Controls 
IL6 rs2069837    
A/A 365 (76.4) 461 (81.2) 0.66 [0.50-0.89]
G/A 105 (22.0) 102 (18.0)
G/G 8 (1.7) 5 (0.9)
IL6 rs2069861    
C/C 442 (91.9) 497 (86.9) 1.74 [1.15-2.63]
T/C 39 (8.1) 70 (12.2)
T/T 0 (0.0) 5 (0.9)
MPO rs8178406   
T/T 151 (31.4) 221 (38.9) 0.78 [0.65-0.95]
T/C 254 (52.8) 262 (46.1)
C/C 76 (15.8) 85 (15.0)
Gene SNP Genotype
Genotype frequency
OR [95% CI] P
0.007
†
0.011
†
0.005
†
Controls, n (%) Cases, n (%)
SNP1 SNP2 SNP3 SNP4
IL1B _TNF rs1143643(IL1B ) rs16944(IL1B ) rs2071590(TNF ) – 8/10 0.517 0.487
IL6 _TNF rs10242595(IL6 ) rs909253(TNF ) – – 10/10 0.549 0.054
IL6 _IL1B rs2069837(IL6 ) rs10242595(IL6 ) rs1143643(IL1B ) – 5/10 0.541 0.145
MPO _TNF rs2071590(TNF ) rs8178406(MPO ) – – 9/10 0.547 0.060
IL6 _MPO rs10242595(IL6 ) rs8178406(MPO ) – – 9/10 0.556 0.031
MPO _IL1B rs1143643(IL1B ) rs16944(IL1B ) rs8178406(MPO ) rs4401102(MPO ) 9/10 0.538 0.160
IL1B _IL6 _TNF_MPO rs10242595(IL6 ) rs1143643(IL1B ) rs8178406(MPO ) rs4401102(MPO ) 8/10 0.527 0.323
P*Genes
Best model
CVC TBA
CI – Confidence Interval  
*OR [95% CI] and P for the log-additive genetic model after adjustment for 
significant covariates (gender, history of hypertension, diabetes, smoking status).  
†Significant result after Bonferroni correction. 
*1000 permutations P.  
CVC – Cross Validation Consistency, TBA – Testing Balanced Accuracy. 
Figure 1 – Interaction dendrogram for the IL6 and MPO polymorphisms in stroke 
susceptibility. The length of the dendrogram branch that connects two 
polymorphisms indicates the strength of interaction (the shorter the branch, the 
stronger is the interaction).  
Stroke pathophysiology is regulated by a combination of environmental, life-style and unclear genetic risk factors.  There is substantial evidence that inflammation within the CNS 
contributes to stroke risk, and known clinical risk factors for stroke, like atherosclerosis, diabetes, obesity, hypertension, and peripheral infection, are associated with an elevated 
systemic inflammatory profile [1-5]. The inflammatory response is equally of major importance in the recovery and healing processes after stroke [6-8]. In this study we tested 
the genetic association of major inflammatory players IL1B (2q14), IL6 (7p21), TNF (6p21.3) and MPO (17q23.1) with stroke susceptibility and with stroke outcome at three 
months after the stroke event. The apparent complexity of the inflammatory mechanisms in stroke, and the multiplicity of players involved suggest a concerted process, in which 
implicated molecules interact to tightly regulate each other. We therefore examined both independent gene effects and the occurrence of gene-gene interactions among the 
tested inflammatory genes in stroke risk and stroke recovery.  
INTRODUCTION 
 Single Nucleotide Polymorphisms (SNPs) covering the IL1B (N=3), IL6 (N=6), TNF (N=3) and MPO (N=2) genes and their 5kb flanking regions were genotyped using the Sequenom 
MassARRAY system (Sequenom, San Diego, USA) or the ABI PRISM 7900HT Sequence Detector System (Applied Biosystems, Foster City).  
 The population sample consisted of 672 patients and 530 controls. A subset of 546 patients were assessed for outcome three months after a stroke event, using the modified 
Rankin Scale (mRS); patients were classified for good or poor recovery (mRS≤1 or mRS>1, respectively).  
 SNPs were tested for association with stroke by logistic regression (using the SNPassoc package of the R software), adjusting for significant demographic, clinical and life-style risk 
factors and/or stroke severity parameters for stroke outcome. Haplotype association analysis was performed with Haploview (4.0 version). Bonferroni correction for multiple testing 
was used to correct significant SNP and haplotype associations.  
Testing for genetic interactions in association with stroke susceptibility and outcome was performed using the multifactor-dimensionality reduction (MDR) method  (v2.0, beta 7.2).  
METHODS 
 Population sample demographic and clinical characteristics  are presented in Table 1.  
 Two contiguous SNPs in the IL6 gene were associated with stroke susceptibility under a 
log-additive model (Table 2), after adjusting for covariates significant in the multivariate 
analysis model – gender, hypertension, diabetes and smoking status. These associations with 
stroke susceptibility remained significant after Bonferroni correction for multiple testing, 
highlighting gene variants with low to moderate effect in stroke risk. 
 One SNP in the MPO gene was significantly associated with stroke susceptibility and this 
association survived Bonferroni correction (Table 2). Interestingly, restricting the analysis to 
ischemic patients showed a more significant association (correctedP=0.006).  
 None of the IL1B and TNF SNPs were associated with stroke susceptibility in this sample. 
 An epistatic interaction between the IL6 and MPO genes was identified in association with 
stroke susceptibility (Table 3). The most significant interaction model was a two-marker 
combination between rs10242595 in IL6 and rs8178406 in MPO, showing a moderately 
increased TBA of 0.556, thus correctly classifying 55.6% of the individuals tested, but a high 
CVC of 9/10, i.e the model was selected 9 times out of 10 cross validation subsets, and a 
global OR=1.69 [95%CI=1.31-2.19]. Interaction between these two markers shows a positive 
information gain (Figure 1), indicating a nonlinear, synergistic relationship between the IL6 
(rs10242595) and the MPO (rs8178406) genes (i.e. epistasis). 
 In the subset of 546 patients assessed for stroke outcome at three months, using the 
modified Rankin Scale (mRS), we found only one IL6 haplotype associated with stroke 
outcome (correctedP=0.024).  
 We provide evidence for a main effect of the IL6 and MPO genes, as well as an epistatic gene 
interaction effect between these two genes, in stroke susceptibility. Our genetic findings thus 
support previous evidence from other research areas for a role of inflammatory molecules in stroke.  
 As the associated IL6 SNPs are not in LD with the widely tested IL6 functional SNP rs1800795, and 
we don’t replicate this association, they likely signal a different IL6 causative variant.  
 We provide novel evidence for the association of the MPO gene with stroke, an effect that was 
largely driven by the ischemic stroke subset. 
The synergistic interaction between IL6 and MPO illustrates the complexity of the inflammatory 
processes in stroke, suggesting that stroke risk is modulated by various genetic factors and by non-
linear gene-gene interactions; our finding is in agreement with a previous in vitro functional study, 
showing that enzymatically inactive MPO induced IL-6 secretion in a dose and time-dependent 
manner by endothelial cells. 
 The complex interplay between genetic background, clinical and life-style factors and the 
environment may ultimately regulate the onset, acute phase and outcome of stroke. We present 
supporting evidence for a role of the IL6 and MPO inflammatory genes in stroke susceptibility, 
modulated by main gene effects together with clinical and life-style factors as well as by gene-gene 
interactions. Our findings are compatible and strengthen previous genetic and biological 
observations, highlighting the need of further functional studies, particularly in view of the possible 
utility of IL-6 as a diagnostic/prognostic stroke biomarker.  
RESULTS 
DISCUSSION & CONCLUSIONS 
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